June 16, 2021 7:45am
Watch what he says, not what he does ...
News: - uniQure N.V. (QURE) announced that the first two patient procedures have been completed in the higher dose, second cohort of the P1/2 clinical trial of AMT-130 for the treatment of Huntington’s disease.
Pre-open indications: 2 BUYs: QURE, EDIT; 2 SELLs: GBT, NTLA; 1 Maintain SELL: BSTG
My version of the morning’s “indications” is about what you need to know; it’s what could happen or materialize after the opening and what might happen during the session
Subscription is coming, it’s not conscription but, an offer to join our collective of like-minded investors!
Dow futures are DOWN -0.13% (-44 points), S&P futures are DOWN -0.03% (-1 point) and NASDAQ futures are UP +0.12% (+17 points)
U.S. stock index futures were creeping up and down mostly flat on Wednesday
European stocks were slightly higher
Asia-Pacific stocks were mixed as investors reacted to data releases in China as well as the Fed’s latest decision.
Data Docket: markets await the outcome of the U.S. Federal Reserve’s policy meeting
- The “Fed” is not expected to make any policy moves, but it could signal that it’s beginning to think about easing its bond-buying policy.
Henry’omics:
Cell and gene therapy sector equities pulled back during Tuesday’s trading session from seven (7) positive closes in a row, a recent record with the S&P 500 closing 0.2% lower after hitting an all-time high earlier in the day. The Dow slid -0.27% and the Nasdaq dipped -0.71%.
RegMed/Cell and Gene Therapy Earnings Scorecard Q1/21 LPS Results … thirty (32 – MESO added) to date … https://www.regmedinvestors.com/articles/11628
Tuesday’s evening’s recap: “the sector stampeded to the downside, told you so!” … https://www.regmedinvestors.com/articles/11956
- The Nasdaq closed DOWN -101.28 points (-0.71%);
- The IBB closed down -1.48% and XBI closed down -2.38%
- Sector volume was LOW with 2 of the 5-upside having higher than the 3-month average volume with the volume of 9 of 29-downside having higher than the 3-month average volume;
- The CBOE Volatility Index (VVIX: INDEX) was up +0.63 points or +3.84% at 17.02
- Tuesday’s percentage (%) of the 5-upside were +0.21% (VYGR) to +2.51% (BLFS) while the 28-downside ranges from -0.10% (ALNY) to -19.30% (SAGE);
Q2/21:
June: 7 positive and 3 negative close
May: 8 positive, 12 negative closes and 1 holiday
April: 11 negative and 10 positive closes
Q1/21:
- March: 10 positive, 12 negative and 1 neutral closes
- February: 9 positive, 10 negative closes and 1 holiday
- January: 10 positive, 9 negative closes and 1 holiday
Companies in my headlights – It’s your decision; I provide an idea and context:
The Biostage (BSTG) - Maintaining Sell – It’s about saying WHAT NEEDS to be written …
Biostage (BSTG) closed down -$0.039 to $1.21 with 10,703 shares traded after Monday’s flat at $1.25 with 2,305 shares traded, Friday’s +$0.04 with 1,395 shares traded to $1.25, Thursday’s +$0.01 to $1.21 with 1,325 shares traded and Wednesday’s +$0.13 to $1.26 with 1,216 shares traded.
Question#`1: Notice the volume numbers per session? WHY the need to “pump, promote and inflate” the share price; does the volume reflects the manipulation to execute the last remaining warrants?
Question#2: Will the annual meeting result in ANY news to/about the future of the company?
Question#3: WHY do I keep writing on BSTG – I was there and then SUDDENLY I wasn’t (there through NO fault of my own other than to UPHOLD the law) and saw WHAT they DID, WERE, KEPT on doing and CONTINUE to do - but, the REAL question to be ANSWERED is WHO is advising them in ALL of these endeavors?
MINORITY PUBLIC shareholders are waiting for the specific time, watching and weighing responses to MAINTAIN their RIGHTS.
The morning’s indications:
BUY:
Editas Medicine (EDIT) closed down -$3.43 to $35.19 and has a bounce-back indication pre-open of +$0.45 or +1.28%
uniQure NV (QURE) closed down $0.43 to $34.46 and NO pre-market indication yet, news - announcing that the first two patient procedures have been completed in the higher dose, second cohort of the P1/2 clinical trial of AMT-130 for the treatment of Huntington’s disease.
SELL:
Global Blood therapeutics (GBT) closed down -$0.73 to $39.55 and has a pre-open negative indication of -$0.25 or -0.63%.
Intellia therapeutics (NTLA) closed up+$0.65 to $88.65 and has a pre-open negative indication of -$2.65 or -2.99%.
The BOTTOM LINE: As we head through these summer months, the cell and gene therapy sector have good clinical results or it doesn’t…. for these valuations “TO STICK”.
News always helps the flow of share pricing however; higher share prices are just temporary or are they about to be deflated?
Wake-up volatility is NOT going away!
I continue to MAINTAIN, this is a confused sector as sentiment rages and fades, momentum is usurped, fundamentals are being ignored – or is it a test of our staying power in certain equities.
It’s going be a long hot summer – expects the fizzle from electronic algorithmic trading until it isn’t!
Although, “I would consider new highs … to be SOLD into …complacency is in store as many investors actually get out to vacations (one indicator).”
A true contrarian thought …
My focus has always been “warning analysis” … my advice, trim and skim any new highs if one can!” I also see a number of lows that could be in the “pick-up” stock game.
My motto, never leave an investor uninformed about what I know!
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
